Mesoblast Posts $120.3 Million in 2026 Revenue as Ryoncil Sales Grow
Key Facts
In a disclosure about its participation in the Australian Securities Exchange’s investor day, published on November 17, 2026, Mesoblast said it presented its transition into a commercial-stage biotechnology company, the growth of Ryoncil and opportunities to expand its cell therapy platform. Against that backdrop, the company recorded total revenue of $120.3 million in fiscal 2026, compared with $17.2 million in the prior year. Net product sales were $115.2 million for the year ended June 30, 2026. The figures show the expansion of the company’s commercial activity in the first full fiscal year after Ryoncil’s launch, according to the company’s fiscal-year materials. The company announced its results for that year on August 27, 2026, before announcing in November that it would take part in the investor day.
Mesoblast said net operating cash burn was $43.8 million in fiscal 2026 and that it ended the year with cash reserves of $102.9 million as of June 30. These figures put operating expenditure and liquidity in the context of the commercial expansion highlighted by the company at the investor day. The company also said it had entered into a five-year, non-dilutive credit facility worth $125 million. The agreement consolidated and retired two higher-cost facilities, according to the company’s fiscal-year disclosure. This reflects one aspect of the financing steps the company reported alongside revenue and product-sales growth.
Gross profit on total sales was $110 million in fiscal 2026, excluding amortization expense, according to Mesoblast’s materials. This provides another measure of commercial performance in the year when the company recorded $115.2 million in net product sales. At the investor day, the company linked its transition to commercial operations with Ryoncil’s growth, placing revenue and gross profit within the broader picture of product development and commercial expansion. The November announcement did not include new financial figures for the year ended in June; it covered the company’s participation and presentation to investors. The annual figures had appeared in an earlier disclosure announced in August.
On clinical development, Mesoblast said it had completed treatment of 350 patients in a Phase 3 trial for chronic low back pain. It also said the registration trial to expand Ryoncil’s label to adults with steroid-refractory acute graft-versus-host disease had begun and was enrolling patients, with 40 U.S. sites targeted. These updates show two separate clinical tracks among the company’s priorities: developing a treatment for back pain and expanding the target population for Ryoncil. The company also presented opportunities to apply its cell therapy platform to multiple high-value indications. The priorities it cited include expanding Ryoncil’s use in adults and developing rexlemestrocel-L for chronic inflammatory low back pain and for cardiac and pulmonary indications.
In the market, MESO shares closed at $12.45 on November 16, 2026, according to EL7 data. That price was from the session before the company’s disclosure, published on November 17, about its participation in the investor day. The financial results for the year ended June 30 had been announced on August 27, so the revenue, cash-burn and reserve figures provide background to the later presentation. The next steps identified by the company focus on continued patient enrollment in the adult Ryoncil trial, which targets 40 U.S. sites, and on developing rexlemestrocel-L for back pain, cardiac and pulmonary indications. The available evidence from the investor-day announcement did not provide new clinical results for these programs.